A small-molecule oral agonist of the human glucagon-like peptide-1 receptor
David A. Griffith,
David J. Edmonds,
Amit S. Kalgutkar,
J. Brent Kuzmiski,
Paula M. Loria,
Aditi R. Saxena,
Scott W. Bagley,
John M. Curto,
David R. Derksen,
João M. Dias,
Matthew C. Griffor,
V. Margaret Jackson,
Margaret S. Landis,
Daniel J. Lettiere,
Alan M. Mathiowetz,
David W. Piotrowski,
David A. Price,
Roger B. Ruggeri,
David A. Tess
Posted 30 Sep 2020
bioRxiv DOI: 10.1101/2020.09.29.319483
Posted 30 Sep 2020
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection. Here we describe the first effective, orally bioavailable small molecule GLP-1R agonists. A sensitized high-throughput screen identified a series of small molecule GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nM potency. These small molecule agonists increased insulin levels in primates but not rodents, which is explained by a cryo-EM structure that revealed a binding pocket requiring primate-specific tryptophan 33. Importantly, oral administration of agonist PF-06882961 to healthy humans produced dose-dependent declines in serum glucose ([NCT03309241]). This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health. One Sentence Summary PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans. ### Competing Interest Statement ASK, AMM, MCG, JMD, CB, CL, SWB, DJL, PML, DRD, JMC, JPF, YL, ARS, DAT, DWP, SH, RBR, MSL, and DAG are employees and stockholders of Pfizer Inc. DAP, DJE, JBK and VMJ are stockholders of Pfizer Inc. : /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03309241&atom=%2Fbiorxiv%2Fearly%2F2020%2F09%2F30%2F2020.09.29.319483.atom
- Downloaded 1,381 times
- Download rankings, all-time:
- Site-wide: 10,574 out of 119,118
- In pharmacology and toxicology: 61 out of 1,038
- Year to date:
- Site-wide: 4,139 out of 119,118
- Since beginning of last month:
- Site-wide: 1,282 out of 119,118
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!